Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 3/20 | 0.47 |
| ▸ | CCR5 | P51681 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4399964 | 0.88 | RORC (0.50) | BCHECCR5MAOBS1PR5SIGMAR1 | |
| SCHEMBL4413002 | 0.88 | RORC (0.50) | BCHECCR5MAOBS1PR5SIGMAR1 | |
| SCHEMBL19994149 | 0.81 | SIGMAR1 (0.51) | MEN1KMT2ASIGMAR1CHRM2CHRM4 | |
| SCHEMBL250507 | 0.79 | BCHE (0.61) | BCHEMAOBALDH1A1S1PR5MEN1 | |
| SCHEMBL11558282 | 0.79 | FUCA1 (0.60) | BCHECCR5MAOBALDH1A1SIGMAR1 | |
| SCHEMBL11558275 | 0.79 | FUCA1 (0.60) | BCHECCR5MAOBALDH1A1SIGMAR1 | |
| SCHEMBL11558271 | 0.79 | FUCA1 (0.60) | BCHECCR5MAOBALDH1A1SIGMAR1 | |
| SCHEMBL13209020 | 0.77 | CCR5 (0.53) | CCR5MAOBALDH1A1S1PR5MEN1 | |
| SCHEMBL8313882 | 0.76 | BCHE (0.70) | BCHEMEN1TSHRKMT2ASIGMAR1 | |
| SCHEMBL10508986 | 0.75 | BCHE (0.56) | BCHEMAOBS1PR5SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056497-A1 | AMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-2119702-A1 | AMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2009-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056497-A1 | AMIDE DERIVATIVE | REN, AGTR1, AGTR2 | BCHE 1015/4885CCR5 3078/4885MAOB 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.